Baseline Anticholinergic Medication Burden in Patients with Overactive Bladder
International Urogynecology Journal · 2025
DOI: 10.1007/s00192-025-06441-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urogynecology Journal, 2025. Verfasst von Morgan Cheeks und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Morgancheeks2020@gmail.com. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Cholinergic Antagonists. Die Arbeit nennt 12 Literaturangaben. Gefördert von: NIA NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
INTRODUCTION AND HYPOTHESIS: The objective of this study is to quantify baseline Anticholinergic Cognitive Burden (ACB) scores among women presenting to a urogynecology practice with overactive bladder (OAB) symptoms and to examine patient characteristics associated with higher baseline ACB scores. METHODS: This retrospective study included women 18 years of age and older presenting as a new patient for evaluation of OAB at an academic urogynecology practice in 2022. A total of 242 patients met the inclusion criteria. Patient baseline characteristics, including medications, were abstracted from the electronic medical record. ACB scores were assessed using a validated four-point scale. OAB treatment after the initial visit was also abstracted. RESULTS: The median ACB score was 1, with 37% of patients having a high-risk ACB score (≥3). Anticholinergics were prescribed to 3% of patients, with 71% of these having high-risk baseline ACB scores. Beta-3 agonists were prescribed to 15%, with 46% of these having high-risk baseline scores. Forty-three percent of patients prescribed beta-3 agonists did not initiate therapy owing to cost. High-risk ACB scores were associated with comorbidities such as hypertension, diabetes, anxiety, and depression. Patients with high-risk ACB scores were more likely to receive sacral neuromodulation. CONCLUSIONS: Many women with OAB have high-risk baseline ACB scores. Although anticholinergics remain commonly prescribed, their cognitive risks necessitate careful patient assessment. Increasing use of safer alternatives such as beta-3 agonists and addressing cost barriers can improve OAB management. Future research should focus on reducing anticholinergic use and addressing inequity in treatment access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Morgancheeks2020@gmail.com.
- Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Förderung
- NIA NIH HHS
- National Institute on Aging
Zitieren
APA
Cheeks, M., Lee, D., Su, S., Andebrhan, S., Lancki, N., & Bretschneider, C. E. (2025). Baseline Anticholinergic Medication Burden in Patients with Overactive Bladder. International Urogynecology Journal. https://doi.org/10.1007/s00192-025-06441-2
Vancouver
Cheeks M, Lee D, Su S, Andebrhan S, Lancki N, Bretschneider CE. Baseline Anticholinergic Medication Burden in Patients with Overactive Bladder. International Urogynecology Journal. 2025. doi:10.1007/s00192-025-06441-2
BibTeX
@article{Cheeks2025,
author = {Cheeks, Morgan and Lee, David and Su, Selma and Andebrhan, Sarah and Lancki, Nicola and Bretschneider, C Emi},
title = {Baseline Anticholinergic Medication Burden in Patients with Overactive Bladder},
journal = {International Urogynecology Journal},
year = {2025},
doi = {10.1007/s00192-025-06441-2}
}
EUVIMED